The drugmaker also loses U.S. patent protection for Cymbalta at the end of this year, and it has been cutting costs as part of its plan to offset the revenue loss. Lilly also is pushing to grow international sales, especially in emerging markets like China, and it is counting on its animal health business and its pipeline of drugs under development.